Last reviewed · How we verify
NCT06908486
Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain
NA trial testing Cognitive Bias Modification for Interpretation in Type 2 Diabetes in 319 participants. Currently enrolling.
15 July 2025
Quick facts
| Lead sponsor | University of Sydney |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 319 |
| Start date | 15 April 2025 |
| Primary completion | 15 July 2025 |
| Estimated completion | 15 October 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Cognitive Bias Modification for Interpretation
- Placebo
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Persistent Pain — all drugs for Persistent Pain →
Sponsor
University of Sydney
Who can join
18 and older, any sex, with Type 2 Diabetes or Persistent Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question\[s\] it aims to answer is whether interpretation bias training away from pain improves pain outcomes. Participants in the CBM-I group will complete 4 online training sessions approximately half an hour each. Each session will present participants with ambiguous scenarios which may be pain-related, however the final word of the sentence will resolve the scenario as benign (thus training participants to make benign interpretations). A measure of interpretation bias will be administered following the fourth training session, and pain severity and interference will be measured at baseline, post-training, two week follow up, and three month follow up. The study hypothesises that participants in the CBM-I group will demonstrate a greater reduction in the co-primary outcomes of pain severity and pain interference over time compared to those in the placebo control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06908486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other University of Sydney trials
Trials by the same sponsor.
- NCT07173335 — Integrated Healthy Lifestyle and Pain Care for People With Musculoskeletal Conditions Living in Rural Areas. · NA · not yet recruiting
- NCT06159660 — Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Function · not yet recruiting
- NCT05568381 — Sleep Disturbance in MCI: A Study of a Cognitive Behavioural Therapy Digital Intervention · NA · completed
- NCT05184790 — LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology · recruiting
- NCT05169177 — Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06908486 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sydney
- Last refreshed: 2 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing